Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
Completed · Phase 2
Conditions studied: Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer, Thyroid Gland Medullary Carcinoma
In brief
This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with metastatic and/or locally advanced or locally recurrent thyroid cancer. Drugs used in chemotherapy, such as suberoylanilide hydroxamic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Suberoylanilide hydroxamic acid may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Key facts
- Study ID
- NCT00134043
- Run by
- National Cancer Institute (NCI)
- People needed
- 19
- Starts
- 2005-12-01
- Expected to finish
- 2009-03-01
- Last updated by the study team
- 2014-08-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed thyroid cancer
- One of the following subtypes:
- Papillary thyroid cancer
- Follicular thyroid cancer
- Hürthle cell thyroid cancer
- Insular thyroid cancer
- Medullary thyroid cancer
- Mixed histology thyroid cancer
- Poorly differentiated thyroid cancer
- Tall-cell thyroid cancer
- Metastatic and/or locally advanced or locally recurrent disease
- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
- Lesions in a previously irradiated area allowed provided there has been subsequent disease progression of the irradiated lesions
- The following are not considered measurable disease:
- Bone lesions
- Leptomeningeal disease
- Ascites
- Pleural or pericardial effusion
- Lymphangitis cutis/pulmonis
- Abdominal masses not confirmed and followed by imaging techniques
- Cystic lesions
- Not a candidate for radioactive iodine I\^131 therapy
- Performance status - ECOG 0-1
- At least 6 months
- WBC ≥ 3,000/mm\^3
Where it is running
- Ohio State University Medical Center — Columbus, Ohio, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.